In preclinical studies, peripherally restricted CB1R antagonists have provided therapeutic efficacy without causing CNS-mediated side effects, which has revitalized the translational potential of peripheral CB1R antagonism in metabolic disorders (6). This evidence concerns the gene CNR1 and Other metabolic disease.